Skip to main navigation Skip to search Skip to main content

Skyscraper: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Project: Research

Project Details

StatusFinished
Effective start/end date09/1/20 → 12/31/25

Funding

  • Syneos Health Limited Liability Company: $189,836.02